Peers of Zevra Therapeutics, Inc. (ZVRA)
Health Care · Pharmaceuticals
Share price divided by TTM earnings per weighted-average shares. Shows how many dollars investors pay for each $1 of yearly profit.
Latest P/E Ratio
10.43x
As of Nov 2, 2026
Beyond P/E Ratio, the valuation view includes forward multiples, EV ratios, cash flow yields, and multi-year chart history for further research.
| Date | P/E Ratio |
|---|---|
| Nov 2, 2026 | 10.43x |
| Oct 30, 2026 | 10.60x |
| Oct 29, 2026 | 10.68x |
| Oct 28, 2026 | 10.63x |
| Oct 27, 2026 | 10.36x |
| Oct 26, 2026 | 9.82x |
| Oct 23, 2026 | 10.11x |
| Oct 22, 2026 | 10.65x |
P/E Ratio = Current Stock Price ÷ Trailing 12-Month (TTM) Diluted EPS (or Market Cap ÷ TTM Net Income). Chartloom divides stock price by trailing twelve-month EPS, calculated by dividing TTM net income by the weighted-average share count from filings. Note: Variations in share-count conventions across data providers may cause slight differences in reported P/E multiples.
Trailing P/E is based on reported GAAP results and is one of the most widely used valuation metrics.
Read the general P/E Ratio definition, formula, and analyst usage guide.
P/E Ratio guideInformational research only; not personalized advice. Values reflect the latest available data on Chartloom and may differ from other sources.
